Our previous study multicenter study of intra-coronary angioscopy after stenting (MICASA) evaluated chronic angioscopic findings after implantation of bare metal stents (BMS) or first-generation and second-generation drug-eluting stents (1st-and 2nd-DES).
Introduction
Our previous study multicenter study of intra-coronary angioscopy after stenting (MICASA) evaluated chronic angioscopic findings after implantation of bare metal stents (BMS) or first-generation and second-generation drug-eluting stents (1st-and 2nd-DES). 1) We found more homogeneous stent coverage by white neointima and less thrombus with 2nd-DES than 1st-DES, corresponding with the better clinical outcomes in patients receiving 2nd-DES. 2) Diabetes mellitus (DM) is associated with an increased risk of adverse clinical outcomes resulting from more advanced systemic atherosclerosis compared to persons without DM. [3] [4] [5] Patients with DM also have a high risk of in-stent restenosis, 6, 7) which is mainly induced by neointimal hyperplasia. Coronary angioscopy is useful for assessing the characteristics of atherosclerotic plaques in vivo, 8) and it has been reported that yellow plaques are commonly identified at culprit lesions causing acute
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Sub-Analysis of a Japanese Multicenter Registry Study (MICASA) coronary syndrome. 9) However, the morphology and distribution of coronary plaques in patients with DM have not been well characterized.
Therefore, the present sub-analysis of MICASA was performed to evaluate the direct influence of DM on medium-term and long-term lesion characteristics in patients treated with various stents and to clarify differences between patients with and without DM.
Material and Methods

Patients
The MICASA is a multicenter registry study of patients undergoing coronary angioscopy at four Japanese institutions. We excluded patients in whom we could not obtain clear angioscopic images because of difficulty in removing blood during the examination.
The study protocol was approved by the ethics committee of each participating institution and written informed consent was obtained from all patients.
Angioscopic examination
Catheterization was done by the radial, brachial, or femoral approach using 6 F or larger catheters, with selective coronary angiography being performed after administration of heparin.
Angioscopy was performed with a VFS-1300 angioscope (Nihon Kohden Tokyo, Japan) and an IF-783V optical fiber (Nihon Kohden). The outer section of the 4 F probe catheter (USCI) was used as a guide for inserting the optical fiber into the target coronary artery. Angioscopic observation was performed while blood was removed from the field of view by injection of 3% dextran-40 through the probe catheter, as reported previously, 10) and images were recorded on a digital recorder.
Evaluation of angioscopic findings
We assessed coverage of the stent struts by neointima (neointi- 
Results
Clinical and lesional characteristics
The baseline clinical and lesional characteristics of the subjects are shown in Table 1 . The interval from stent implantation to coronary angioscopy was 279.0 ± 82.7 days in patients with DM and 266.3 ± 83.0 days in patients with non-DM. Although many variables were well balanced between the two groups, PCI was performed more often for lesions of the right coronary artery and the stents used were longer in patients with DM.
Angioscopic findings
We evaluated the following five angioscopic findings: Max-NC, Min-NC, heterogeneity index, YC grade, and the prevalence of thrombus. The YC grade tended to be lower in patients with DM than in patients with non-DM when all stents were assessed together (1.0 ± 0.8 vs. 1.2 ± 0.9, P = 0.050) (Fig. 1) . Among le- sions treated with BMS, the heterogeneity index tended to be higher in patients with DM than in patients with non-DM (2.0 ± 0.9 vs. 1.0 ± 0.9, P = 0.050) (Fig. 2) . Furthermore, Min-NC was higher and the YC grade was lower for lesions treated by 1st-DES in patients with DM compared with patients with non-DM (Min-NC: 0.7 ± 0.6 vs. 0.4 ± 0.5, P = 0.009; YC grade: 1.2 ± 0.9 vs. 1.7 ± 0.9, P = 0.006) (Fig. 3) . In contrast, there were no significant differences of any angioscopic findings between patients with and without DM for lesions treated with 2nd-DES (Fig. 4) . The heterogeneity index of bare metal stents was higher in patients with DM (n = 6) than in those without DM (n = 9).
Fig. 3
Angioscopic findings for 1st-DES Minimum neointimal coverage of 1st-DES was significantly greater and plaque was significantly less yellow in patients with DM (n = 32) than in patients without DM (n = 55). 1st-DES: first generation drugeluting stents.
Predictors of yellow plaque
We evaluated the predictors of yellow plaque, which was defined as grade 2 or 3 YC. When multiple lesions were observed in the same patient, these were counted as one. After excluding six lesions for this reason, serum low-density lipoprotein (LDL) data were reviewed in 222 patients, including 85 patients with yellow plaque. Multivariate analysis showed that 1st-DES, acute coronary syndrome, and an LDL cholesterol level ≥ 100 mg/dl were independent positive predictors of yellow plaque (grade 2 or 3 YC), while DM was a negative predictor (P <0.001, OR:
5.475; P = 0.001, OR: 2.978; P = 0.007, OR: 2.491; and P = 0.048, OR: 0.600, respectively) ( Table 2) .
Relationship between YC grade and LDL cholesterol
We evaluated the relationship between the YC grade of plaque and LDL cholesterol in 222 patients with serum LDL data. The LDL level was lower in patients with DM than in patients with non-DM, although the difference was not significant (82.8 ± 24.9 vs. 89.1 ± 26.3 mg/dl, P = 0.146) (data not shown in Tables). The YC grade was significantly higher in the 63 patients with LDL cholesterol levels ≥ 100 mg/dl than in the 159 patients with LDL cholesterol levels < 100 mg/dl (1.5 ± 1.0 vs. 1.0 ± 0.8, P = 0.001) ( Table 3) . This relationship was the same in patients with or without DM ( Table 3) . Angioscopic findings for 2nd-DES There were no significant differences of the findings for 2nd-DES between patients with DM (n = 61) and patients without DM (n = 98). 2nd-DES: second generation drug-eluting stents. 
Discussion
The present sub-analysis of MICASA demonstrated that minimum neointimal coverage of 1st-DES was significantly greater and the YC grade was significantly lower in patients with DM than in patients without DM. In addition, DM was found to be a significant negative predictor of yellow plaque. This is the first reported evidence that patients with DM have less yellow plaque.
In general, DM is associated with acceleration of coronary atherosclerosis that increases the risk of major adverse cardiac events.
12) The hyperglycemic state itself has a crucial role in the excess cardiovascular risk associated with diabetes thanks to an enhanced thrombotic milieu and endothelial dysfunction related to increased oxidative stress. 13) Multimodal coronary imaging studies have shown that coronary atherosclerosis and plaque vulnerability (including the number of yellow plaques and maximum YC grade) are more advanced even in prediabetic patients, 8) that there is more frequent disruption of silent plaque in the nonischemic coronary arteries of diabetic patients, 14) and that the lipid cores of plaques are longer in diabetic patients than nondiabetic patients. 15) These reports might suggest that the YC grade would be higher or thrombus would be more frequent in patients with DM than patients with non-DM, but we found a lower YC grade in patients with DM. The following reasons for this result can be suggested. First, we investigated coronary arteries with lesions treated by stenting. If diffuse and accelerated neointimal proliferation within the stented segment is more frequent in patients with DM than in those without DM, 5) this would lead to greater late loss, a thicker fibrous cap, and a lower YC grade. On the other hand, it has been reported that patients with DM have immature neointimal tissue 16) or a neointima composed of organized thrombus due to delayed re-endothelialization, resulting in higher YC grades. 17) Therefore, investigation of more patients is needed to resolve this issue. Second, glycemic control was good in many of our patients (Hemoglobin A1c
[HbA1c]: 6.86 ± 0.98%), which might have suppressed the pro-atherosclerotic effect of DM. Third, about 85% of the patients with DM were on aggressive statin lipid-lowering therapy, and their LDL level was lower than that of the patients without DM. Another angioscopic study 18) has shown that statin therapy reduces the YC grade of plaques, presumably reflecting a decrease of the lipid content.
Although late loss is reported to be less marked after implantation of 1st-DES than BMS, 7) we found that the grades of high Min-NC and low YC were more significant for 1st-DES. Some comparisons of clinical outcomes and impacts 19, 20) between 1st-DES and 2nd-DES in patients with DM have already been reported, but little has been published about angioscopic coronary lesion characteristics. Previous investigators have noted an uneven distribution of the neointima after implantation of SES or PES, 21) as well as an association between a higher residual plaque burden in reference vessel segments and edge stenosis in patients receiving SES, PES, and BMS. 22, 23) The SPIRIT V diabetes study 24) showed that EES were associated with less intimal hyperplasia than PES, while the safety outcome was comparable. Furthermore, Iwasaki et al. 25) reported that the average neointimal thickness and coverage of EES were similar in patients with or without DM. Therefore, the negative impact of In the present study, the YC grade was significantly higher in patients with an LDL cholesterol level ≥ 100 mg/dl than in patients with LDL cholesterol < 100 mg/dl. Atheroma volume is reported to show a correlation with the cholesterol profile 27) and the serum LDL cholesterol concentration is known to affect both plaque composition and volume. 28) It was reported that lipid-lowering therapy with statins is associated with early improvement of the color of vulnerable yellow plaques 26) and with a greater increase in the fibrous cap of coronary plaques. 29) Our results were consistent with these reports. The YC grade was higher in patients with an LDL cholesterol level ≥ 100 mg/dl, even if they were on statin therapy. Control of DM was good in the present study, suggesting that regulation of LDL cholesterol may have had more influence on the YC grade than DM. Furthermore, the LDL level was lower in our patients with DM than in those without DM. Clinicians tend to monitor patients closely when they have DM complicated by dyslipidemia, so the lower LDL level achieved in patients with DM could have contributed to their lower YC grade compared to the patients without DM.
In this study, acute coronary syndrome was also a predictor of yellow plaque. One of the most important etiologies of acute coronary syndrome is vulnerable plaque and plaque rupture with occlusive thrombosis. Acute-phase lesion characteristics might have an influence on the characteristics in the chronic phase.
Despite the above-mentioned considerations, it is difficult to fully explain why patients with DM showed less yellow plaque, especially after 1st-DES implantation. However, the present study was not a large-scale prospective trial, but a retrospective real-world clinical study that provided data relevant to routine practice.
This study had several limitations. First, the patient population was small, so further studies involving a larger number of subjects are warranted. Second, detailed data were not obtained about the duration of DM or its treatment, including insulin therapy and the drugs used or the dosages for statin therapy. Third, we could not specify the number of excluded cases. Fourth, we can only observe the luminal surface of the coronary artery by angioscopy. Fifth, Quantitative Coronary Angiography (QCA) data were not obtained in this study.
Conclusions
The yellow color grade of stented lesions was lower in patients with DM than in patients without DM, especially those treated with 1st-DES. The stent type, clinical setting, and LDL cholesterol level were positive predictors of yellow plaque, while DM was a negative predictor.
